Recent News
On August 19, 2025, multiple outlets reported Phase II data for VK2735 showing up to 12.2% body-weight reduction over ~13 weeks while also citing elevated discontinuation rates for active arms versus placebo (reported discontinuations ranged from ~20% to 28%). The same period saw market reaction with shares trading down sharply after results were released. Additional coverage noted a previously announced manufacturing agreement and ongoing evaluation of tolerability and dosing strategies.
Technical Analysis
ADX and Directional Indicators: ADX at 25.1 signals emerging trend strength. DI+ at 20.52 shows a dip-and-reversal pattern, which indicates bullish directional pressure. DI- at 32.62 shows a dip-and-reversal pattern as well, which indicates bearish directional pressure. The coexistence of rising DI- and rising DI+ alongside ADX near 25.1 suggests directional conflict while trend strength develops.
MACD: MACD at -1.74 with a peak-and-reversal pattern and a signal line at -1.64 indicates bearish momentum; MACD sits below its signal line and shows a downward shift in momentum rather than a bullish cross above the signal line.
MRO (Momentum/Regression Oscillator): MRO at -35.42 sits negative, which indicates price below the regression target and implies potential upward pressure as price seeks convergence toward target levels; the MRO shows a dip-and-reversal pattern.
RSI and Price Structure: RSI at 47.24 with a dip-and-reversal pattern places momentum near neutral-to-moderate levels and favors a rebound bias rather than persistent overbought pressure. Price closed at $26.04, below the 200-day average of $31.23 and inside the lower Bollinger band envelope (within the -2x standard deviation band), consistent with a short-term oversold or mean-reversion setup while volatility remains elevated.
Moving Averages, Ichimoku and Volatility: Shorter EMAs show dip-and-reversal behavior (12-day EMA $25.46; 26-day EMA $27.30), price sits beneath the 50-day average $30.65, and the Chikou span lies within the Ichimoku cloud—these features indicate consolidation with potential for directional change once momentum confirms. 42-day beta 3.12 and 52-week beta 1.69 confirm above-average sensitivity to market moves; recent volume at 8,271,766 exceeded the 10-day and 200-day averages, underlining the heightened trading interest around trial news.
Fundamental Analysis
Profitability & Income Statement: Operating loss (EBIT) of $-74,574,000 and net income of $-65,561,000 reflect ongoing negative operating performance. EPS actual registered $-0.58 versus an estimate of $-0.44, producing an EPS surprise of -31.82%.
Cash, Liquidity & Capital Structure: Cash and short-term investments total $807,724,000 with cash alone at $33,880,000. Free cash flow registered $-47,061,000 and operating cash flow $-67,657,000. Current ratio stands at 25.86 (current assets $827,017,000; current liabilities $31,980,000), above the industry peer mean of 3.94 and above the reported industry peer high of 24.70, indicating exceptional near-term liquidity on the balance sheet. Total debt equals $878,000, producing debt-to-assets of 0.106% and debt-to-equity of 0.11%, both well below the industry peer mean values, reflecting minimal leverage.
Returns and Growth: Return on assets at -7.737% and return on equity at -8.242% sit below the industry peer mean values, while reported earnings growth QoQ equals 47.42% and earnings growth YoY equals -279.67% (use these period-specific figures when assessing recent performance dynamics). Research and development expense totaled $60,153,000, consistent with a clinical-stage investment profile.
Valuation Context: Price-to-book at 4.32 sits below the industry peer mean of 5.28 and below the industry peer median of 6.29. Forward EPS remains negative (forward EPS $-0.3775) and forward PE is negative at -73.53. Market capitalization stands at $3,439,749,116 with enterprise value $2,632,903,116. Free cash flow yield registers negative at -1.37%. The current valuation as determined by WMDST classifies the stock as under-valued, driven primarily by sizable cash reserves and minimal debt offsetting negative operating cash flow and clinical-stage execution risk.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-06-30 |
| REPORT DATE: | 2025-07-23 |
| NEXT REPORT DATE: | 2025-10-22 |
| CASH FLOW | Begin Period Cash Flow | $ 37.9 M |
| Operating Cash Flow | $ -67.66 M | |
| Capital Expenditures | — | |
| Change In Working Capital | $ 7.2 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ -4.06 M | |
| End Period Cash Flow | $ 33.9 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | $ 112.0 K | |
| Depreciation and Amortization | $ 112.0 K | |
| Research and Development | $ 60.2 M | |
| Total Operating Expenses | $ 74.6 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ -74.46 M | |
| EBIT | $ -74.57 M | |
| Operating Income | $ -74.57 M | |
| Interest Income | $ 9.0 M | |
| Interest Expense | — | |
| Net Interest Income | $ 9.0 M | |
| Income Before Tax | $ -65.56 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -65.56 M | |
| Net Income From Continuing Operations | $ -65.56 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.44 | |
| EPS Actual | $ -0.58 | |
| EPS Difference | $ -0.14 | |
| EPS Surprise | -31.818 % | |
| Forward EPS | $ -0.38 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 827.9 M | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 795.5 M | |
| Total Current Assets | $ 827.0 M | |
| Cash and Short-Term Investments | $ 807.7 M | |
| Cash | $ 33.9 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | $ 5.5 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 32.0 M | |
| Net Debt | — | |
| Total Debt | $ 878.0 K | |
| Total Liabilities | $ 32.4 M | |
| EQUITY | ||
| Total Equity | $ 795.5 M | |
| Retained Earnings | $ -599.10 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 7.08 | |
| Shares Outstanding | 112.330 M | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | $ 3.4 B |
| Enterprise Value | $ 2.6 B | |
| Enterprise Multiple | -35.359 | |
| Enterprise Multiple QoQ | -20.55 % | |
| Enterprise Multiple YoY | -77.69 % | |
| Enterprise Multiple IPRWA | high: 47.216 median: 17.473 mean: 5.682 VKTX: -35.359 low: -68.907 |
|
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.041 | |
| Asset To Liability | 25.559 | |
| Debt To Capital | 0.001 | |
| Debt To Assets | 0.001 | |
| Debt To Assets QoQ | -7.826 % | |
| Debt To Assets YoY | 49.296 % | |
| Debt To Assets IPRWA | high: 0.995 mean: 0.195 median: 0.062 VKTX: 0.001 low: 0.0 |
|
| Debt To Equity | 0.001 | |
| Debt To Equity QoQ | -6.78 % | |
| Debt To Equity YoY | 50.685 % | |
| Debt To Equity IPRWA | high: 1.577 mean: 0.256 median: 0.059 VKTX: 0.001 low: -1.039 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 4.324 | |
| Price To Book QoQ | 10.49 % | |
| Price To Book YoY | -37.055 % | |
| Price To Book IPRWA | high: 16.592 median: 6.295 mean: 5.285 VKTX: 4.324 low: -10.064 |
|
| Price To Earnings (P/E) | -49.649 | |
| Price To Earnings QoQ | -31.039 % | |
| Price To Earnings YoY | -82.611 % | |
| Price To Earnings IPRWA | high: 44.732 mean: -10.885 median: -18.364 VKTX: -49.649 low: -73.374 |
|
| PE/G Ratio | -1.197 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | -73.531 | |
| Forward PE/G | -1.773 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 795.5 M | |
| Net Invested Capital | $ 795.5 M | |
| Invested Capital | $ 795.5 M | |
| Net Tangible Assets | $ 795.5 M | |
| Net Working Capital | $ 795.0 M | |
| LIQUIDITY | ||
| Cash Ratio | 25.257 | |
| Current Ratio | 25.86 | |
| Current Ratio QoQ | -41.553 % | |
| Current Ratio YoY | -31.384 % | |
| Current Ratio IPRWA | VKTX: 25.86 high: 24.698 mean: 3.941 median: 2.52 low: 0.021 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -0.012 | |
| Cost Of Debt | 2.55 % | |
| Interest Coverage Ratio | -3107.25 | |
| Interest Coverage Ratio QoQ | 34.443 % | |
| Interest Coverage Ratio YoY | 64.241 % | |
| Interest Coverage Ratio IPRWA | high: 677.4 mean: 35.835 median: 2.347 low: -1465.352 VKTX: -3107.25 |
|
| Operating Cash Flow Ratio | -2.116 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -4.515 % | |
| Revenue Growth | — | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | — | |
| Earnings Growth | 41.463 % | |
| Earnings Growth QoQ | 47.424 % | |
| Earnings Growth YoY | -279.672 % | |
| Earnings Growth IPRWA | high: 155.0 % VKTX: 41.463 % mean: 14.776 % median: 11.33 % low: -175.0 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -47.06 M | |
| Free Cash Flow Yield | -1.368 % | |
| Free Cash Flow Yield QoQ | -13.363 % | |
| Free Cash Flow Yield YoY | 203.326 % | |
| Free Cash Flow Yield IPRWA | high: 36.371 % median: 0.516 % mean: -0.333 % VKTX: -1.368 % low: -74.318 % |
|
| Free Cash Growth | -10.071 % | |
| Free Cash Growth QoQ | -114.847 % | |
| Free Cash Growth YoY | -102.76 % | |
| Free Cash Growth IPRWA | high: 157.51 % median: 13.562 % mean: 3.708 % VKTX: -10.071 % low: -193.262 % |
|
| Free Cash To Net Income | 0.718 | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | 1.032 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -7.737 % | |
| Return On Assets QoQ | 50.525 % | |
| Return On Assets YoY | 232.774 % | |
| Return On Assets IPRWA | high: 36.544 % median: 1.616 % mean: -1.348 % VKTX: -7.737 % low: -68.545 % |
|
| Return On Capital Employed (ROCE) | -9.37 % | |
| Return On Equity (ROE) | -0.082 | |
| Return On Equity QoQ | 52.97 % | |
| Return On Equity YoY | 241.142 % | |
| Return On Equity IPRWA | high: 1.141 median: 0.04 mean: 0.008 VKTX: -0.082 low: -1.572 |
|
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |